扶正化瘀胶囊联合恩替卡韦分散片治疗慢性乙型肝炎肝纤维化临床研究

目的:观察扶正化瘀胶囊联合恩替卡韦分散片治疗慢性乙型肝炎肝纤维化的临床疗效。方法:选取慢性乙型肝炎肝纤维化患者60例,按治疗方法分为对照组和观察组各30例。对照组给予恩替卡韦分散片治疗,观察组在对照组基础上加用扶正化瘀胶囊治疗。比较2组治疗6个月后的临床疗效及肝功能、肝纤维化四项、肝脏硬度、中医证候积分以及不良反应发生率。结果:治疗6个月后,总有效率观察组为93.3%,对照组为73.3%,2组比较,差异有统计学意义(P<0.05)。治疗后,2组丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、总胆红素(TBil)水平较治疗前降低,且观察组ALT、AST、TBil水平低于对照组,差异均有统计学意义(P<0.05)。治疗后,2组透明质酸(HA)、层黏蛋白(LN)、Ⅲ型前胶原(PCⅢ)、Ⅳ型胶原(Ⅳ-C)水平较治疗前降低,且观察组HA、LN、PCⅢ、Ⅳ-C水平低于对照组,差异均有统计学意义(P<0.05)。治疗后,2组肝脏硬度值(LSM)、中医证候积分较治疗前降低,且观察组LSM、中医证候积分低于对照组,差异均有统计学意义(P<0.05)。结论:扶正化瘀胶囊联合恩替卡韦分散片治疗慢性乙型肝炎肝纤维化临床疗效较好,能够改善肝功能,减轻肝纤维化程度。

Clinical Study on Fuzheng Huayu Capsules Combined with Entecavir Dispersible Tablets for Liver Fibrosis in Chronic Hepatitis B

Objective: To observe the clinical effect of Fuzheng Huayu capsules combined with entecavir dispersible tablets for liver fibrosis in chronic hepatitis B. Methods:A total of 60 cases of patients with liver fibrosis in chronic hepatitis B were selected and divided into the control group and the observation group according to the remedy,30 cases in each group.The control group was treated with entecavir dispersible tablets, and the observation group was additionally treated with Fuzheng Huayu capsules based on the treatment of the control group. After six-month treatment,the clinical effect,liver function, four parameters of liver fibrosis, liver stiffness, Chinese medicine syndrome scores and incidence of adverse reactions in the two groups were compared. Results:After six-month treatment,the total effective rate was 93.3% in the observation group, higher than that of 73.3% in the control group, the difference being significant(P<0.05). After treatment, the levels of alanine aminotransferase(ALT), aspartate aminotransferase(AST), total bilirubin(TBil) in the two groups were decreased when compared with those before treatment,and the levels in the observation group were lower than those in the control group,differences being significant(P<0.05). After treatment,the levels of hyaluronic acid(HA),laminin(LN),procollagen type Ⅲ(PCⅢ) and type Ⅳ collagen(Ⅳ-C) in the two groups were decreased when compared with those before treatment, and the levels in the observation group were lower than those in the control group, differences being significant(P<0.05). After treatment,liver stiffness measure(LSM) and Chinese medicine syndrome scores in the two groups were decreased when compared with those before treatment,the LSM and Chinese medicine syndrome scores in the observation group were lower than that in the control group,differences being significant(P<0.05). Conclusion:Fuzheng Huayu capsules combined with entecavir dispersible tablets has good clinical effect in treating liver fibrosis in chronic hepatitis B,which can improve the liver function and relieve liver fibrosis.